$599

Altimmune Q2 ’26 Earnings; AZ Ph3 Eleco HF Study; Insilico New Lp(a) Asset; Lilly Black Market Reta Commentary

A series of cardiometabolic-related news items has been observed from Altimmune, AstraZeneca, Insilico Medicine, and Lilly. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here